WO2002002583A1 - Sel amine de compose de lignane - Google Patents
Sel amine de compose de lignane Download PDFInfo
- Publication number
- WO2002002583A1 WO2002002583A1 PCT/JP2001/005194 JP0105194W WO0202583A1 WO 2002002583 A1 WO2002002583 A1 WO 2002002583A1 JP 0105194 W JP0105194 W JP 0105194W WO 0202583 A1 WO0202583 A1 WO 0202583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amine salt
- compound
- trimethoxy
- getylamine
- naphthalene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/033—Uronic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the present invention, c relates Amin salt Ridanan compound
- R ° is hydrogen or a hydrophilic group
- R 1 is a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, a cycloalkyl which may have a substituent A lower alkyl group, an aryl group which may have a substituent, an aralkyl group which may have a substituent, or a hetero ring which may have a substituent;
- R and may have a substituent A lower alkyl group or an optionally substituted aralkyl group;
- R 4 , R 5 , R 6 , R 7 , and R 8 each represent lower alkyl
- the lignan compound represented by or a salt thereof is useful for various pharmaceutical uses, particularly as an antihyperlipidemic agent or a bile acid reabsorption inhibitor (Japanese Patent Application Laid-Open No. 9-241210). No. 6).
- the present inventor has found that a redanane compound represented by the following formula (II), which is included in the above formula (I), is particularly useful as a medicament, but this compound is not a crystalline substance.
- several purifications by column chromatography were essential. In addition, the yield was poor.
- an amine salt is not specifically described as a salt of the compound (I). Disclosure of the invention
- the present inventors have found that the compound can be crystallized by converting the compound into an amine salt.
- the present invention has been completed based on these findings. That is, by crystallizing the compound represented by the formula (II) into an amine salt and crystallizing the compound, the compound can be purified and easily isolated from the reaction mixture by a method such as filtration.
- the isolated amine salt of the compound can be easily converted to a free compound by desalting treatment with a dilute acid or the like.
- the crude product of the compound of the formula (II) is dissolved in a suitable solvent, for example, an alcoholic solvent such as methanol / ethanol, ethanol, isopropyl alcohol and the like, and an ether solvent such as ether and THF.
- a suitable solvent for example, an alcoholic solvent such as methanol / ethanol, ethanol, isopropyl alcohol and the like, and an ether solvent such as ether and THF.
- aromatic hydrocarbons such as toluene, xylene, etc.
- adding the amine mixing at 0 to 100 ° C, preferably from room temperature to 70 ° C, and cooling from room temperature to 0 ° C as necessary. Thereafter, the precipitated crystals may be collected by filtration and washed with the used solvent. Getylamine is preferred as the amine used.
- the obtained amine salt of the compound of the formula (II) is treated with an acid such as a dilute acid as described above.
- the compound can be easily converted back to the free compound.
- the amine salt of the present invention is useful as an intermediate, but may itself be used as a pharmaceutically active ingredient. Therefore, the present invention also provides a medicine containing the amine salt, for example, an antihyperlipidemic agent.
- the amine salt of the present invention may be a solvate such as a hydrate or an alcohol solvate.
- the filtrate was extracted with ethyl acetate, and the extract was washed with water, a saturated aqueous solution of sodium hydrogencarbonate, and a saturated saline solution, and then dried over anhydrous magnesium sulfate.
- the solvent was distilled off under reduced pressure to obtain 5.0 g of a crude product of compound (3). This was used for the next reaction without purification.
- the diffraction pattern of the compound (5) by powder X-ray diffraction was as follows.
- IR v (CHCI3) 3591, 3483, 3327, 2964, 1743, 1697, 1608, 1516, 1464, 1415, 1352, 1242, 1 138, 1095, 1065, 1030.
- Powder X-ray diffraction of compound (1) The diffraction pattern was as follows. The measurement conditions are the same as in Example 1. 9 ⁇ 062 S62I ⁇ 99 ⁇ 0 009 '82
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/312,617 US6864241B2 (en) | 2000-06-30 | 2001-06-19 | Amine salt of lignan compounds |
CA002412290A CA2412290A1 (en) | 2000-06-30 | 2001-06-19 | Amine salt of lignan compound |
EP01938731A EP1310505A4 (en) | 2000-06-30 | 2001-06-19 | AMINE SALT OF LIGNANE COMPOUND |
AU2001264316A AU2001264316A1 (en) | 2000-06-30 | 2001-06-19 | Amine salt of lignan compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-198043 | 2000-06-30 | ||
JP2000198043 | 2000-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002002583A1 true WO2002002583A1 (fr) | 2002-01-10 |
Family
ID=18696264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005194 WO2002002583A1 (fr) | 2000-06-30 | 2001-06-19 | Sel amine de compose de lignane |
Country Status (7)
Country | Link |
---|---|
US (1) | US6864241B2 (ja) |
EP (1) | EP1310505A4 (ja) |
KR (1) | KR20030016309A (ja) |
CN (1) | CN1231489C (ja) |
AU (1) | AU2001264316A1 (ja) |
CA (1) | CA2412290A1 (ja) |
WO (1) | WO2002002583A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09241206A (ja) * | 1996-03-01 | 1997-09-16 | Shionogi & Co Ltd | リグナン系化合物 |
-
2001
- 2001-06-19 AU AU2001264316A patent/AU2001264316A1/en not_active Abandoned
- 2001-06-19 CA CA002412290A patent/CA2412290A1/en not_active Abandoned
- 2001-06-19 EP EP01938731A patent/EP1310505A4/en not_active Withdrawn
- 2001-06-19 WO PCT/JP2001/005194 patent/WO2002002583A1/ja not_active Application Discontinuation
- 2001-06-19 KR KR1020027017828A patent/KR20030016309A/ko not_active Application Discontinuation
- 2001-06-19 US US10/312,617 patent/US6864241B2/en not_active Expired - Fee Related
- 2001-06-19 CN CNB018146120A patent/CN1231489C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09241206A (ja) * | 1996-03-01 | 1997-09-16 | Shionogi & Co Ltd | リグナン系化合物 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1310505A4 * |
TOSHIRO YAMAGUCHI ET AL.: "Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs", ARZNEIM.-FORSCH., vol. 48, no. 10, 1998, pages 995 - 1006, XP002943457 * |
Also Published As
Publication number | Publication date |
---|---|
US6864241B2 (en) | 2005-03-08 |
CN1231489C (zh) | 2005-12-14 |
EP1310505A1 (en) | 2003-05-14 |
KR20030016309A (ko) | 2003-02-26 |
CA2412290A1 (en) | 2002-01-10 |
EP1310505A4 (en) | 2005-12-07 |
AU2001264316A1 (en) | 2002-01-14 |
US20030119758A1 (en) | 2003-06-26 |
CN1449404A (zh) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2471795A1 (en) | Method for preparing prasugrel | |
IE45962B1 (en) | 4-trifluoromethylbenzoic acid derivatives | |
CA2410227A1 (en) | Crystal modification of fexofenadine | |
JPH08506332A (ja) | テトラゾール−5−カルボン酸誘導体の製法 | |
WO2002002583A1 (fr) | Sel amine de compose de lignane | |
EP1853561A1 (en) | PROCESS FOR PRODUCING POLYMORPH FORM (I) OF l-BENZYL-4- [(5, 6-DIMETHOXY-l-INDANONE) -2YL]METHYL PIPERIDINE HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE) | |
JPH0242083A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
JPH0546332B2 (ja) | ||
JPH0136462B2 (ja) | ||
JPH0357895B2 (ja) | ||
RU2333916C1 (ru) | Способ получения бетулоновой кислоты | |
HU213315B (en) | Process for producing arylacetic acids and their alkali metal salts | |
RU2035459C1 (ru) | Способ получения 5-оксипроизводных 2,3-дигидро-4,6,7-триметил-2-(rs)-бензофурануксусной кислоты | |
JPH05500797A (ja) | ケトン化合物の調製についての改良された方法 | |
NZ527138A (en) | 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same | |
JPH03181485A (ja) | 7―(d―2―アミノ―2―フェニルアセトアミド)―3―セフェム―4―カルボン酸一水和物の製造方法及びその方法で生成される中間体 | |
CN109053847B (zh) | 一种17β-咪唑烷基溴盐-去氢表雄烷衍生物及其制备方法和应用 | |
JP4587529B2 (ja) | イピダクリン及び塩酸イピダクリン水和物の製造方法 | |
JPS59116298A (ja) | 6,8−置換−アデノシン−3′,5′−環状リン酸及びその塩の製法 | |
EP0823907A1 (en) | NEW PROCESS FOR PREPARING (-)-TRANS-N-p-FLUOROBENZOYLMETHYL-4-(p-FLUOROPHENYL)-3- 3,4-(METHYLENEDIOXY)PHENOXY]METHYL]-PIPERIDINE | |
JPH02233692A (ja) | 新規なn↑6,2′―o―ジ置換―アデノシン―3′,5′―環状リン酸及びその製法 | |
JPS58188862A (ja) | N−アシルカルノシンの製造法 | |
JP2504934B2 (ja) | 1,6,7−トリアシルフオルスコリン誘導体 | |
JPH06166655A (ja) | テトラメトキシメチルベンズアルデヒドの製造方法 | |
JPS62108877A (ja) | 2−(10,11−ジヒドロ−10−オキソジベンゾ〔b,f〕チエピン−2−イル)プロピオン酸の精製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2002 507835 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412290 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001938731 Country of ref document: EP Ref document number: 10312617 Country of ref document: US Ref document number: 1020027017828 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018146120 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017828 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001938731 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001938731 Country of ref document: EP |